510(k) device
BlueStar CGM insulin dose calculator
Welldoc, Inc. · Continuous Glucose Monitor Informed Insulin Dose Calculator (QRX, Class II) · First FDA decision Aug 11, 2023, newest Aug 11, 2023Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "BlueStar CGM"
MAUDE reports
0
Brand "BlueStar CGM", since 2015
PubMed studies
0
Mentioning "BlueStar CGM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing BlueStar CGM insulin dose calculator
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K222888 · Decided Aug 11, 2023 · 322 days after receipt
Device type: Continuous Glucose Monitor Informed Insulin Dose Calculator (QRX) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
- Home Blood Glucose MonitorsNational analysisReview closedCAG-00161NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "BlueStar CGM", any status and sponsor, newest update first.
WelldocNot on our public-company list
NCT05343065 · 27 participants · Start Jul 5, 2022 · Primary completion Dec 20, 2022
Device: BlueStar 10 · For: Diabetes Mellitus
Sites: Baltimore, Maryland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BlueStar CGM", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QRX
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BlueStar CGM"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QRX.
- SmartBolus CalculatorInsulet Corporation · 510(k) 2023
- MODI SystemDreaMed Diabetes, Ltd. · 510(k) 2026
- Dexcom Smart BasalDexcom, Inc. · 510(k) 2025
- Omnipod 5 SmartBolus CalculatorInsulet Corporation · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.